Key takeaways
Abacavir (Ziagen) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are both used to treat HIV, but they have some key differences. Abacavir (Ziagen) is a single medication that belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is available in both generic and brand forms. It should be used in combination with other HIV medications. It requires a genetic test before use due to the risk of severe allergic reactions. Genvoya, on the other hand, is a combination of four medications: two NRTIs (emtricitabine and tenofovir alafenamide), an integrase strand transfer inhibitor (INSTI) called elvitegravir, and a booster called cobicistat. It is a complete HIV regimen. Genvoya is taken once daily with food and is not available as a generic. While both medications can cause side effects like nausea and diarrhea, Genvoya has additional risks such as kidney problems and more interactions with other medications. Abacavir (Ziagen) is unique in that it can be used safely in people with severe kidney problems, whereas Genvoya requires careful monitoring for kidney and liver issues.
